COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,010 Articles (22,627 medRxiv, 8,383 bioRxiv)

Most recent first Previous |  Page 494: Articles 4931-4940  | Next

Addressing spatial misalignment in population health research: a case study of US congressional district political metrics and county health data
Nethery, R. C., Testa, C., Tabb, L. P., Hanage, W. P., Chen, J. T., Krieger, N.
10.1101/2023.01.10.23284410 — Posted: 2023-01-11
Using early detection data to estimate the date of emergence of an epidemic outbreak
Jijon, S., Czuppon, P., Blanquart, F., Debarre, F.
10.1101/2023.01.09.23284284 — Posted: 2023-01-11
Vaccine effectiveness against SARS-CoV-2 Delta and Omicron infection and infectiousness within households in the Netherlands between July 2021 and August 2022.
Hoeve, C. E., de Gier, B., Huiberts, A. J., de Melker, H. E., Hahne, S. J. M., van den Hof, S., Knol, M. J.
10.1101/2023.01.10.23284386 — Posted: 2023-01-11
Bayesian sequential approach to monitor COVID-19 variants through positivity rate from wastewate
Montesinos Lopez, J. C., Daza-Torres, M. L., Garcia, Y. E., Herrera, C., Bess, C. W., Bischel, H. N., Nuno, M.
10.1101/2023.01.10.23284365 — Posted: 2023-01-11
Did COVID-19 or COVID-19 vaccines influence the patterns of Dengue in 2021: An exploratory analysis of two observational studies from North India
Kaur, U., Jethwani, P., Mishra, S., Dehade, A., Yadav, A. K., Chakrabarti, S., Chakrabarti, S. S.
10.1101/2023.01.09.23284366 — Posted: 2023-01-11
Estimating the impact of test-trace-isolate-quarantine systems on SARS-CoV-2 transmission in Australia
Shearer, F. M., McCaw, J. M., Ryan, G. E., Hao, T., Tierney, N., Lydeamore, M., Ellis, S., Ward, K., Wood, J., McVernon, J., Golding, N.
10.1101/2023.01.10.23284209 — Posted: 2023-01-11
Building case investigation and contact tracing programs in U.S. state and local health departments: a conceptual framework
Woodward, A., Rivers, C.
10.1101/2023.01.07.23284294 — Posted: 2023-01-11
Safety, tolerability, and immunogenicity of a new SARS-CoV-2 recombinant Gamma variant RBD-based protein adjuvanted vaccine, used as heterologous booster in healthy adults: a Phase 1 interim report.
Pasquevich, K. A., Coria, L. M., Ceballos, A., Mazzitelli, B., Rodriguez, J. M., Demaria, A., Pueblas Castro, C., Bruno, L., Saposnik, L., Salvatori, M., Varese, A., Gonzalez, S., Gonzalez Martinez, V. V., Geffner, J., Alvarez, D., Laboratorio Pablo Cassara R&D and CMC group for ARVAC-CG, , Feleder, E. C., Halabe, K. E., Perez Lera, P. E., Montes de Oca, F., Vega, J. C., Lombardo, M., Yerino, G. A., Flo, J., Cassataro, J.
10.1101/2023.01.10.22284009 — Posted: 2023-01-11
Inspiration of SARS-CoV-2 envelope protein mutations on pathogenicity of Omicron XBB
Gao, Z.-b., Wang, Y., Ji, H., Zuo, X., Xia, B.
10.1101/2023.01.09.523338 — Posted: 2023-01-10
Human iPS cell-derived sensory neurons can be infected by SARS-CoV-2 strain WA1/2020 as well as variants delta and omicron.
Flamier, A., Bisht, P., Richards, A., Tomasello, D. L., Jaenisch, R.
10.1101/2023.01.10.523422 — Posted: 2023-01-10

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).